Glaucoma Physician – Nicox Begins Second Phase 3 Trial of NCX 470

Nicox said Denali is a 3-month phase 3 trial evaluating the safety and efficacy of NCX 470 ophthalmic solution, 0.1%, vs the current standard of care, latanoprost ophthalmic solution, 0.005%, for the lowering of IOP in patients with open-angle glaucoma or ocular hypertension. The trial, which will also include a long-term safety extension, is expected to randomize 650+ patients, at…

Read the full article here

Related Articles